Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 13598
Country/Region: Rwanda
Year: 2018
Main Partner: Johns Hopkins University
Main Partner Program: JHPIEGO
Organizational Type: University
Funding Agency: USDOD
Total Funding: $970,398 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $0
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $970,398
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $0
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $0
Treatment: Pediatric Treatment (PDTX) $0
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
TX_NEW_TA By Age/Sex: 10-14 Male 2019 2
TX_NEW_TA By Age/Sex: 15-19 Male 2019 8
TX_NEW_TA By Age/Sex: 20-24 Male 2019 19
TX_NEW_TA Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 80
TX_NEW_TA Sum of Age/Sex disaggregates 2019 29
TX_NEW_TA TX_NEW_N_TA_Age_Sex_HIVStatus 25-29, Male, Positive 2019 19
TX_NEW_TA TX_NEW_N_TA_Age_Sex_HIVStatus 30-34, Male, Positive 2019 20
TX_NEW_TA TX_NEW_N_TA_Age_Sex_HIVStatus 35-39, Male, Positive 2019 8
TX_NEW_TA TX_NEW_N_TA_Age_Sex_HIVStatus 40-49, Male, Positive 2019 4
VMMC_CIRC_DSD By Age: 10-14 2019 3,485
VMMC_CIRC_DSD By Age: 15-19 2019 20,551
VMMC_CIRC_DSD By Age: 20-24 2019 5,849
VMMC_CIRC_DSD By Age: 25-29 2019 1,906
VMMC_CIRC_DSD By circumcision technique: Device-based VMMC 2019 12,674
VMMC_CIRC_DSD By circumcision technique: Surgical VMMC 2019 29,573
VMMC_CIRC_DSD Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2019 42,248
VMMC_CIRC_DSD Sum of age disaggregates (FY15-Current) 2019 31,791
VMMC_CIRC_DSD Sum of age disaggregates (Prior to FY15) 2019 29,885
VMMC_CIRC_DSD VMMC_CIRC_N_DSD_Age_Sex 30-34, Male 2019 5,577
VMMC_CIRC_DSD VMMC_CIRC_N_DSD_Age_Sex 35-39, Male 2019 4,183
VMMC_CIRC_DSD VMMC_CIRC_N_DSD_Age_Sex 40-49, Male 2019 697